NeuroOne Medical Technologies Corporation cash flow to debt ratio of -1.06K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

NeuroOne Medical Technologies Corporation's free cash flow has increased -73.78% from $-11.13M last year to $-2.92M, signaling increasing performance

NeuroOne Medical Technologies Corporation's debt to equity ratio is 0.04, which means that the company's assets are healthy financed, signaling financial stability.

NeuroOne Medical Technologies Corporation's debt has decreased relative to shareholder equity from 0.32 last year to 0.04 today, signaling strengthened financials

NeuroOne Medical Technologies Corporation has a net cash position, so leverage is healthy.

NeuroOne Medical Technologies Corporation's interest coverage ratio of 21.76 indicates that earnings with good margin can cover interest payments on company debt

NeuroOne Medical Technologies Corporation's profit margin has increased (-80.84%) in the last year from -356.74% to -68.34%, signaling increasing performance

NeuroOne Medical Technologies Corporation's short-term assets of $10.23M exceed its short-term liabilities of $2.30M

NeuroOne Medical Technologies Corporation's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

NeuroOne Medical Technologies Corporation's return on equity of -98.33%, is lower than 15.00%, indicating bad performance

NeuroOne Medical Technologies Corporation's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

NeuroOne Medical Technologies Corporation had positive net income in only 0 out of 5 years, indicating unstable earnings

NeuroOne Medical Technologies Corporation has negative free cash flow, indicating the company is burning cash rather than generating it

NeuroOne Medical Technologies Corporation has negative free cash flow, indicating cash burn

NeuroOne Medical Technologies Corporation's yearly earnings has increased -70.73% since last year from $-12.32M to $-3.61M, signaling increasing performance

NeuroOne Medical Technologies Corporation's yearly revenue has increased 250.35% since last year from $3.45M to $12.10M, signaling increasing performance

ROIC -112.33% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

NeuroOne Medical Technologies Corporation's 3-year revenue CAGR of 313.45% is positive, indicating growing revenue over the past 3 years

NeuroOne Medical Technologies Corporation had revenue growth in 3 out of 5 years, indicating consistent revenue performance

NeuroOne Medical Technologies Corporation had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

NeuroOne Medical Technologies Corporation has insufficient data to evaluate this check.

NeuroOne Medical Technologies Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

NeuroOne Medical Technologies Corporation is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

NeuroOne Medical Technologies Corporation has negative or missing EBITDA, making EV/EBITDA ratio unreliable

NeuroOne Medical Technologies Corporation has insufficient data to evaluate this check.

NeuroOne Medical Technologies Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

NeuroOne Medical Technologies Corporation has a price-to-book ratio of 2.45x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

NeuroOne Medical Technologies Corporation has a price-to-sales ratio of 1.35x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue